Fixed-dose combination (antiretroviral)

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Fixed-dose combinations of antiretrovirals are multiple antiretroviral drugs combined into a single pill, which helps reduce pill burden. They may combine different classes of antiretrovirals or contain only a single class. Licensed fixed-dose combinations are shown in the table below.

Brand Name Drug Names (INN) Date of FDA Approval Company
Combivir zidovudine + lamivudine September 26, 1997 GlaxoSmithKline
Trizivir abacavir + zidovudine + lamivudine November 15, 2000 GlaxoSmithKline
Kaletra lopinavir + ritonavir September 15, 2000[1] Abbott Laboratories
Epzicom (in USA)
Kivexa (in Europe)
abacavir + lamivudine August 2, 2004 GlaxoSmithKline
Truvada emtricitabine + tenofovir August 8, 2006[2] Gilead Sciences
Atripla efavirenz + emtricitabine + tenofovir July 12, 2006[3] Gilead Sciences
Bristol-Myers Squibb
Complera rilpivirine + emtricitabine + tenofovir August 10, 2011[4] Gilead Sciences
Johnson & Johnson
Stribild elvitegravir + cobicistat + emtricitabine + tenofovir August 27, 2012 Gilead Sciences

See also[edit]

References[edit]

  1. ^ "FDA approval of new formulation of Kaletra". FDA. October 28, 2005. "The original formulation was approved on September 15, 2000" 
  2. ^ "Traditional approval of Viread and Truvada". FDA. March 8, 2006. "VIREAD and TRUVADA had received accelerated approval on Oct. 26, 2001 and August 2, 2004, respectively" 
  3. ^ "FDA approval of Atripla, 3-drug fixed dose combination antiretroviral". FDA. July 12, 2006. 
  4. ^ "Approval of Complera: emtricitabine/rilpivirine/tenofovir DF fixed dose combination". FDA. August 10, 2011.